Christopher Uhde

Christopher Uhde is a Senior Pharma & Biotech Equity Analyst at SEB since July 2019, specializing in areas such as myeloma, haemophilia, and gene therapy, and significantly improved SEB's ranking in Pharma/Biotech equity research. Prior to this role, Christopher worked at ABG Sundal Collier from October 2017 to June 2019 as a Biotech Equity Analyst, where coverage included Sobi and Oncopeptides, contributing to a jump in ranking within the sector. Christopher also served as a Drug Discovery Postdoctoral Researcher at Karolinska Institutet from 2016 to 2017, focusing on treatments for Major Depression. Educational credentials include a PhD in Neurodevelopmental Systems Biology from Karolinska Institutet, and an MSc in Embryo Stem Cell Neurogenesis, along with a BSc in Biological Sciences from The University of Edinburgh. Academic foundations were laid at The King's School, Canterbury, with A & A/S levels in relevant subjects.